BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 17591936)

  • 1. Microfluidic chips for detecting the t(4;14) translocation and monitoring disease during treatment using reverse transcriptase-polymerase chain reaction analysis of IgH-MMSET hybrid transcripts.
    VanDijken J; Kaigala GV; Lauzon J; Atrazhev A; Adamia S; Taylor BJ; Reiman T; Belch AR; Backhouse CJ; Pilarski LM
    J Mol Diagn; 2007 Jul; 9(3):358-67. PubMed ID: 17591936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Detection of IgH-MMSET fusion gene in multiple myeloma patients and its significance].
    Jiang H; Hou J; Chen YB; Ding SQ
    Zhonghua Xue Ye Xue Za Zhi; 2003 Oct; 24(10):515-8. PubMed ID: 14690579
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of t(4;14)(p16.3;q32) chromosomal translocation in multiple myeloma by reverse transcription-polymerase chain reaction analysis of IGH-MMSET fusion transcripts.
    Malgeri U; Baldini L; Perfetti V; Fabris S; Vignarelli MC; Colombo G; Lotti V; Compasso S; Bogni S; Lombardi L; Maiolo AT; Neri A
    Cancer Res; 2000 Aug; 60(15):4058-61. PubMed ID: 10945609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma.
    Dring AM; Davies FE; Fenton JA; Roddam PL; Scott K; Gonzalez D; Rollinson S; Rawstron AC; Rees-Unwin KS; Li C; Munshi NC; Anderson KC; Morgan GJ
    Clin Cancer Res; 2004 Sep; 10(17):5692-701. PubMed ID: 15355895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression.
    Keats JJ; Reiman T; Maxwell CA; Taylor BJ; Larratt LM; Mant MJ; Belch AR; Pilarski LM
    Blood; 2003 Feb; 101(4):1520-9. PubMed ID: 12393535
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A subset of multiple myeloma harboring the t(4;14)(p16;q32) translocation lacks FGFR3 expression but maintains an IGH/MMSET fusion transcript.
    Santra M; Zhan F; Tian E; Barlogie B; Shaughnessy J
    Blood; 2003 Mar; 101(6):2374-6. PubMed ID: 12433679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Translocation T(4;14)(p16.3;q32) is a recurrent genetic lesion in primary amyloidosis.
    Perfetti V; Coluccia AM; Intini D; Malgeri U; Vignarelli MC; Casarini S; Merlini G; Neri A
    Am J Pathol; 2001 May; 158(5):1599-603. PubMed ID: 11337357
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitive detection using microfluidics technology of single cell PCR products from high and low abundance IgH VDJ templates in multiple myeloma.
    Pilarski LM; Lauzon J; Strachan E; Adamia S; Atrazhev A; Belch AR; Backhouse CJ
    J Immunol Methods; 2005 Oct; 305(1):94-105. PubMed ID: 16150455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The t(4;14) translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET, resulting in IgH/MMSET hybrid transcripts.
    Chesi M; Nardini E; Lim RS; Smith KD; Kuehl WM; Bergsagel PL
    Blood; 1998 Nov; 92(9):3025-34. PubMed ID: 9787135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential nuclear organization of translocation-prone genes in nonmalignant B cells from patients with t(14;16) as compared with t(4;14) or t(11;14) myeloma.
    Martin LD; Harizanova J; Righolt CH; Zhu G; Mai S; Belch AR; Pilarski LM
    Genes Chromosomes Cancer; 2013 Jun; 52(6):523-37. PubMed ID: 23460268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a novel IGH-MMSET fusion transcript in a human myeloma cell line with the t(4;14)(p16.3;q32) chromosomal translocation.
    Intini D; Fabris S; Storlazzi T; Otsuki T; Ciceri G; Verdelli D; Lombardi L; Rocchi M; Neri A
    Br J Haematol; 2004 Aug; 126(3):437-9. PubMed ID: 15257719
    [No Abstract]   [Full Text] [Related]  

  • 12. Global real-time quantification/reverse transcription-polymerase chain reaction for detecting proto-oncogenes associated with 14q32 chromosomal translocation in multiple myeloma.
    Tajima E; Uranishi M; Iida S; Komatsu H; Nitta M; Ueda R
    Haematologica; 2005 Apr; 90(4):559-62. PubMed ID: 15820958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Newly diagnosed multiple myeloma patients carrying monoallelic deletion of the whole locus of immunoglobulin heavy chain gene have a better prognosis compared to those with t(4;14) and t(14;16).
    Duek A; Trakhtenbrot L; Amariglio N; Benyamini N; Zilbershats I; Ganzel C; Shevetz O; Leiba R; Rozic G; Nagler A; Leiba M
    Genes Chromosomes Cancer; 2019 Aug; 58(8):516-520. PubMed ID: 30675954
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR3 is expressed and is important for survival in INA-6, a human myeloma cell line without a t(4;14).
    Våtsveen TK; Brenne AT; Dai HY; Waage A; Sundan A; Børset M
    Eur J Haematol; 2009 Nov; 83(5):471-6. PubMed ID: 19594619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FGFR3 amplification in the absence of IGH@-FGFR3 fusion t(4;14) in myeloma.
    Quintero-Rivera F; El-Sabbagh Badr R; Rao PN
    Cancer Genet Cytogenet; 2009 Nov; 195(1):92-3. PubMed ID: 19837276
    [No Abstract]   [Full Text] [Related]  

  • 16. A molecular study of the t(4;14) in multiple myeloma.
    Sibley K; Fenton JA; Dring AM; Ashcroft AJ; Rawstron AC; Morgan GJ
    Br J Haematol; 2002 Aug; 118(2):514-20. PubMed ID: 12139740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of ID-1 as a potential target gene of MMSET in multiple myeloma.
    Hudlebusch HR; Theilgaard-Mönch K; Lodahl M; Johnsen HE; Rasmussen T
    Br J Haematol; 2005 Sep; 130(5):700-8. PubMed ID: 16115125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic characterization of the chromosomal breakpoints of t(4;14) of multiple myeloma suggests more than one possible aetiological mechanism.
    Fenton JA; Pratt G; Rawstron AC; Sibley K; Rothwell D; Yates Z; Dring A; Richards SJ; Ashcroft AJ; Davies FE; Owen RG; Child JA; Morgan GJ
    Oncogene; 2003 Feb; 22(7):1103-13. PubMed ID: 12592397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Double-hit myeloma with IGH/MYC and IGH/CCND1 translocations.
    Ji M; Jang S; Lee JH; Seo EJ
    Ann Hematol; 2013 Aug; 92(8):1129-31. PubMed ID: 23307601
    [No Abstract]   [Full Text] [Related]  

  • 20. High incidence of translocations t(11;14)(q13;q32) and t(4;14)(p16;q32) in patients with plasma cell malignancies.
    Avet-Loiseau H; Li JY; Facon T; Brigaudeau C; Morineau N; Maloisel F; Rapp MJ; Talmant P; Trimoreau F; Jaccard A; Harousseau JL; Bataille R
    Cancer Res; 1998 Dec; 58(24):5640-5. PubMed ID: 9865713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.